Variant Allele Frequency Stratification and EGFR Co-mutation Characteristics in AKT1 E17K-mutant Non-small Cell Lung Cancer
摘要
背景与目的 AKT丝氨酸/苏氨酸激酶1(AKT serine/threonine kinase 1,AKT1)E17K是AKT1基因最常见的激活突变,在乳腺癌中已被确立为可靶向的驱动事件.然而该突变在非小细胞肺癌(non-small cell lung cancer,NSCLC)中极为罕见,临床意义尚不明确.变异等位基因频率(variant allele frequency,VAF)可在一定程度上反映突变克隆占比,本研究通过分析NSCLC中AKT1 E17K的VAF与表皮生长因子受体(epidermal growth factor receptor,EGFR)等经典驱动基因的共突变关系,探索该突变在肿瘤克隆演化中的潜在意义.方法 回顾性分析首都医科大学附属北京胸科医院2019年6月至2026年4月肺癌患者下一代测序(next-generation sequencing,NGS)数据,13,003例次检测去重后为11,368例独立患者(含小细胞肺癌),检出AKT1 E17K阳性35例(总体检出率为0.31%),均为NSCLC,剔除5例外院会诊病例后纳入30例.以VAF连续变量分析为主要分析,以10%为探索性界值进行分组比较.结果 30例患者中腺癌20例(66.7%),中位随访12个月(范围:1-55个月).高VAF组(≥10%,17例)EGFR共突变率(11.8%,2/17)低于低VAF组(<10%,13例;46.2%,6/13),校正前P为0.049[比值比(odds ratio,OR)=0.156],Bonferroni校正后差异无统计学意义(P=0.246);EGFR共突变阳性组VAF中位数低于阴性组(1.37%vs 13.73%,P=0.071);连续变量分析显示VAF与EGFR共突变呈负相关趋势(ρ=-0.340,P=0.066).Firth校正Logistic回归调整组织学类型后,高VAF与EGFR共突变减少的关联方向不变,但不再具有统计学差异(OR=0.21,95%CI:0.03-1.33,P=0.097).结论 AKT1 E17K VAF与EGFR共突变呈负相关趋势,但该关联经多重比较校正及组织学类型调整后均无统计学显著性,可能部分受组织学类型构成影响.本研究结果应作为探索性发现,仍需多中心大样本研究证实.
Background and objective AKT serine/threonine kinase 1(AKT1)E17K,the most common activat-ing mutation of AKT1,is an established druggable driver in breast cancer;however,it is exceedingly rare in non-small cell lung cancer(NSCLC),with its clinical significance remaining unclear.Variant allele frequency(VAF)may partially reflect the clonal proportion of a mutation,offering clues to the clonal characteristics of such rare mutations.This study investigated the relation-ship between AKT1 E17K VAF and co-mutation with classic driver genes such as epidermal growth factor receptor(EGFR)in NSCLC,aiming to explore the potential role of this mutation in tumor clonal evolution.Methods Next-generation sequencing(NGS)data of lung cancer patients at Beijing Chest Hospital,Capital Medical University from June 2019 to April 2026 were retrospectively analyzed.After deduplication of 13,003 tests,11,368 unique patients(including small cell lung cancer)were identified,among whom 35 harbored AKT1 E17K mutations(overall detection rate 0.31%),all being NSCLC;5 external consultation cases were excluded,leaving 30 cases for analysis.Continuous VAF analysis was designated as the primary analysis,with an exploratory cutoffof 10%.Results Of the 30 patients,20(66.7%)were adenocarcinoma.Median follow-up was 12 months(range:1-55 months).The EGFR co-mutation rate was lower in the high-VAF group(≥10%,n=17)than in the low-VAF group(<10%,n=13;11.8%vs 46.2%),reaching nominal significance before correction[P=0.049,odds ratio(OR)=0.156]but not after Bonferroni adjustment(adjusted P=0.246).The median VAF was lower in the EGFR co-mutated group than in the EGFR wild-type group(1.37%vs 13.73%,P=0.071).Continuous analysis showed a negative trend be-tween VAF and EGFR co-mutation(ρ=-0.340,P=0.066).After adjusting for histological type using Firth-corrected Logistic regression,the direction of the association remained unchanged but was no longer nominally significant(OR=0.21,95%CI:0.03-1.33,P=0.097).Conclusion AKT1 E17K VAF showed a negative trend with EGFR co-mutation;however,the as-sociation did not remain significant after correction for multiple comparisons or adjustment for histological type,and may be partly influenced by histological composition.These findings should be regarded as hypothesis-generating and require validation in larger multi-center cohorts.